Blog
RSS FeedPosted by Michael Wonder on 01 Feb 2025
Groundbreaking one-off gene therapy approved for severe sickle cell disease
31 January 2025 - People in England with severe sickle cell disease will be among the first to receive treatment using ...
Posted by Michael Wonder on 31 Jan 2025
Vertex announces Casgevy reimbursement agreement for the treatment of sickle cell disease in England
31 January 2025 - Agreement means eligible sickle cell disease patients in England now have access to Casgevy. ...
Posted by Michael Wonder on 08 Aug 2024
Vertex announces Casgevy reimbursement agreement for the treatment of transfusion-dependent beta thalassemia in England
7 August 2024 - Eligible transfusion-dependent beta thalassaemia patients in England will be able to access the therapy from today. ...
Posted by Michael Wonder on 20 Oct 2021
Coverage with evidence development schemes for medical devices in Europe: characteristics and challenges
20 October 2021 - Medical devices are potentially good candidates for coverage with evidence development schemes, as clinical data at market ...
Posted by Michael Wonder on 22 Apr 2021
Delcath Systems announces revised NICE guidance for Chemosat in the United Kingdom
21 April 2021 - Recommends special arrangement designation which increases reimbursement options. ...
Posted by Michael Wonder on 16 Sep 2015
NICE proposes further research for Dupuytren’s contracture treatment
16 September 2015 - NICE has today confirmed its previous final draft guidance not to recommend collagenase clostridium histolyticum (Xiapex, Swedish ...
Posted by Michael Wonder on 26 Aug 2015
NICE green light for Sankyo's bloodthinner Lixiana
25 August 2015 - The National Institute for Health and Care Excellence has issued a final recommendation for Sankyo’s blood thinner ...
Posted by Michael Wonder on 26 Aug 2015
Final NICE green light for Takeda's Entyvio
26 August 2015 - Crohn’s disease patients can now get routine access to treatment with Takeda’s biologic Entyvio on the National ...